# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN-TD
- Date: 1917-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin. **S**

## History of present illness

Madam Walker returns two weeks after her sick visit for gastroenteritis. The vomiting and diarrhea settled within two days, and she restarted losartan and empagliflozin once she had eaten normally for a day. The potassium and creatinine check due two to four weeks after the losartan increase was not done: she was on a three-week convention tour and her office had booked no laboratory day. The panel planned for the week after the sick visit was also missed when she left on another trip. Her home readings on losartan 100 mg average 134/84. She has had no dizziness, cough, genital itching or muscle aches. She is asking for sauces on the side and no added salt at banquets. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 134/84 on losartan 100 mg |
| Missed checks | Panel after the losartan increase, and the panel a week after the gastroenteritis |
| Gastroenteritis | Resolved; losartan and empagliflozin restarted after a day of normal eating |
| Side effects | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness; weight back up by 0.8 kg since the illness |
| Gastrointestinal | Negative | Bowels normal |
| Cardiovascular | Negative | No ankle swelling |
| Genitourinary | Negative | No burning or genital itching |
| Musculoskeletal | Negative | No muscle aches |

5 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet each morning **S**
- Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgery **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/86 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 77.2 kg; BMI 29.1 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.7 mmol/L; Bicarbonate (total CO2): 24 mmol/L; Creatinine: 1.31 mg/dL (high); eGFR (CKD-EPI 1912, race-free): 50 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 176 mg/g (high); Total cholesterol: 172 mg/dL; LDL cholesterol: 98 mg/dL; HDL cholesterol: 48 mg/dL (low); Triglycerides: 130 mg/dL; ALT: 22 U/L. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.7 mmol/L at this visit **S**
- Bicarbonate (total CO2): 25 mmol/L at baseline, 24 mmol/L at this visit **S**
- Creatinine: 1.22 mg/dL (high) at baseline, 1.31 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 1912, race-free): 54 mL/min/1.73 m² (low) at baseline, 50 mL/min/1.73 m² (low) at this visit **S**
- Urine albumin-to-creatinine ratio: 286 mg/g (high) at baseline, 176 mg/g (high) at this visit **S**
- Total cholesterol: 250 mg/dL (high) at baseline, 172 mg/dL at this visit **S**
- LDL cholesterol: 174 mg/dL (high) at baseline, 98 mg/dL at this visit **S**
- HDL cholesterol: 46 mg/dL (low) at baseline, 48 mg/dL (low) at this visit **S**
- Triglycerides: 150 mg/dL (high) at baseline, 130 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 136/86, pulse 76; weight 77.2 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Abdomen | Soft, non-tender |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension with chronic kidney disease** (I12.9). Above goal on the maximum losartan dose: home 134/84, clinic 136/86. **S**
   - Add amlodipine 5 mg daily.
   - Home readings daily for a week, then twice a week.
   - Watch for ankle swelling.
2. **Chronic kidney disease G3a A2** (N18.31). Urine albumin-to-creatinine ratio 176 mg/g, 39% below the baseline of 286 to 294. Potassium 4.7 mmol/L; creatinine 1.31 mg/dL (eGFR 50), back from 1.46 during the gastroenteritis to its on-treatment level. Both missed checks caused no harm judging by the sick-visit panel and today's results. **S**
   - Continue losartan 100 mg and empagliflozin.
   - Her office will book every laboratory check on a home day before trips are scheduled.
   - Urine albumin and kidney function at six months.
3. **Hyperlipidemia** (E78.5). LDL 98 mg/dL on atorvastatin 20 mg, 44% lower than 174; ALT 22 U/L; no muscle aches. **S**
   - Continue atorvastatin 20 mg; yearly lipid panel.
4. **Viral gastroenteritis** (A08.4). Resolved; kidney function recovered. **S**
   - Sick-day rules reviewed again; they worked.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings) | Every visit | Completed today | 136/86 |
| Self-management | Home blood pressure readings | Two readings morning and evening for seven days to confirm and after each change; then twice a week, travel days included | Completed today | Average 134/84 |
| Examination | Weight and BMI | Every visit | Completed today | 77.2 kg |
| Laboratory | Potassium, bicarbonate, creatinine and eGFR (CKD-EPI 1912, race-free) | Two to four weeks after starting or increasing losartan or empagliflozin; then every six months | Deferred | Missed: the panel due two to four weeks after the losartan increase was not done because she was on a three-week tour with no laboratory day booked, and the panel planned a week after the gastroenteritis was missed for another trip. No harm judging by the sick-visit panel (potassium 4.9 mmol/L, creatinine 1.46 mg/dL while volume depleted) and today's results (potassium 4.7 mmol/L, bicarbonate 24 mmol/L, creatinine 1.31 mg/dL, eGFR 50). Corrective action: her office books each laboratory check on a home day before trips are scheduled (INT-012) |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; about three months after a treatment change; then every six months for G3a A2 | Completed today | 176 mg/g, 39% lower |
| Laboratory | Lipid panel and ALT | 4 to 12 weeks after starting a statin, then yearly | Completed today | LDL 98, total cholesterol 172, HDL 48, triglycerides 130 mg/dL; ALT 22 U/L |
| Medication safety | Medicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zones | Every visit | Completed today | Sick-day rules applied correctly during the gastroenteritis; no side effects; amlodipine added |
| Self-management | Sodium and diet counseling | Every visit | Completed today | Sauces on the side and no added salt at banquets; water on travel days |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within six months, lower toward a systolic of 120 if well tolerated. In progress; target 1917-08-17. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% within six months. In progress; target 1917-08-17. **S**
- Kidney function stable, without a fall in eGFR of more than 30% after starting treatment. In progress; target 1917-08-17. **S**
- Sodium under 2 g a day using foods she likes, at home and on the road. In progress; target 1917-08-17. **S**
- LDL cholesterol lower by at least 30%. Outcome by 1917-04-27: 174 to 98 mg/dL on atorvastatin 20 mg, 44% lower. **S**
- Care that fits her work: every check scheduled around her travel, by her choice. In progress; target 1917-08-17. **S**

## Medication changes

- Started: Amlodipine 5 mg oral tablet, one tablet daily **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American College of Cardiology and American Heart Association (Circulation 2019)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026), Aether Forge

## Follow-up

- Preventive visit in about six weeks. Six-month review in the summer with urine albumin, kidney function and hemoglobin, booked on a home day. Call for ankle swelling, dizziness, or vomiting or diarrhea (hold losartan and empagliflozin). **S**
- Next scheduled visit 1917-06-08: periodic adult preventive visit. **S**
